(MENAFN- Gulf Times) Gene therapy for patients with a severe form of the blood disorder beta-thalassaemia could be safe and effective as well as end the need for transfusions, results from the clinical trials show.
Beta-thalassaemia is a genetic disorder that impairs the body's ability to produce a key component of haemoglobin — a critical protein in red blood cells that carries oxygen to organs and tissue.
People with the most severe forms of beta-thalassaemia require monthly blood transfusions, right from their toddler age, to replenish their red blood cell supplies along with iron chelation to remove extra iron from the body.
Frequent transfusions, however, can cause serious complications due to iron toxicity and viral infections.
The results, published in New England Journal of Medicine, showed that a one-time treatment with the gene therapy known as LentiGlobin BB305 vector reduced or eliminated the need for blood transfusions in 22 patients with severe beta-thalassaemia.
'We saw remarkable outcomes using LentiGlobin gene therapy, with most patients no longer needing monthly transfusions, said lead author Alexis Thompson, from Ann & Robert H. Lurie Children's Hospital of Chicago.
'These study results exceeded our expectations with clinical benefit for nearly all patients and suggest that gene therapy may be an effective treatment for thalassaemia in the future, Thompson added.
Of the 22 patients aged between 12 and 35 years, 15 patients achieved transfusion-free status, while others needed transfusions less often.
All the patient underwent chemotherapy, after which they were infused with their own stem cells that were treated in the lab with a modified virus to replace the gene that is defective in thalassaemia. Patients typically reached peak production of haemoglobin in 9-12 months after infusion.
'While these gene therapy trials were the largest for thalassaemia to date, we need to evaluate effectiveness in a much larger population, Thompson said, adding that they 'are now enrolling patients as young as five-years-old on a Phase 3 trial. IANS
MENAFN2104201800670000ID1096750698
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.